Pain Management

The alert was implemented after passage of a state senate bill.

Study results add to the body of evidence demonstrating the efficacy of CGRP inhibitors for migraine treatment and prophylaxis.

This treatment is the first and only long-acting buprenorphine injectable with weekly and monthly doses.

A new meta-analysis found duloxetine to be the only commonly prescribed medication that was effective.

Only the 60 mg dose of atogepant is approved for chronic migraine prevention.

A new study from JAPHA explores the link between OUD and social factors.

Naloxone hydrochloride nasal spray (Narcan) 4 mg is expected to be available over the counter in late summer 2023.

Vitamin D supplementation may be an effective and safe adjunctive prophylactic therapy to topiramate for children who experience migraine attacks, showed a study conducted in Saudi Arabia.

The test is intended to complement the company’s TBI plasma test, which received FDA clearance in 2021.

Nerivio received clearance in January 2021 for use in acute migraine.

The letter outlined 7 steps that the Biden administration can take without the need for additional legislation.

The number of digital therapeutics available for migraine is likely to expand.

Long, hot showers and cold, dry air can contribute to psoriasis flare-ups during the winter months.

New legislation removes what many perceived as a barrier to treating opioid use disorder.

The PDUFA date has been set for May 22, 2023.

Women on Medicaid with opioid use disorder (OUD) who use medications for opioid use disorder (MOUD) are more likely to use contraception and to undergo female sterilization than peers not prescribed MOUD.

Patients are finding relief in alternative therapies for this chronic skin disease.

Take a look back at our most popular pain management coverage for 2022.

Biosimilar medications stand to significantly increase cost savings for patients.

New pathways of care are needed to improve health care spending.

Investigators set out to evaluate how medication access for certain rheumatic conditions has changed since June 2022.

Results from a randomized controlled trial study suggest dextromethorphan may even worsen patient pain experience.

We may be one step closer to nonprescription naloxone.

As the main course of treatment for cancer-related pain, the use of opioids comes with a number of issues for both patients and prescribers.

Cannabinoids lack the habit-forming mechanism of action found in methadone and buprenorphine, unlocking new potential for the drug.

Positive effects emerge when patients get medical care, avoid deadly fentanyl-laced street drugs.

Study finds growth in three years after CDC guideline for primary care clinicians.

Are prescription cap laws for opioids effective for children and teenagers?

Used to treat a variety of concerns and found in many medicine cabinets, new research indicates that nonsteroidal anti-inflammatory drugs may pose a risk to patients with type 2 diabetes.